U.S., Sept. 22 -- ClinicalTrials.gov registry received information related to the study (NCT07830238) titled 'SNC116 Therapy for Relapsed/Refractory B-cell Acute Lymphoblastic Leukemia' on Sept. 10.
Brief Summary: This study aims to evaluate the safety and pharmacokinetic profile of SNC116 in adult patients with relapsed/refractory B-cell acute lymphoblastic leukemia
Study Start Date: Sept., 2026
Study Type: INTERVENTIONAL
Condition:
B-cell Acute Lymphoblastic Leukemia
Intervention:
DRUG: SNC116
Subjects will receive SNC116 injection per different dose level
Recruitment Status: NOT_YET_RECRUITING
Sponsor: Shanghai Simnova Biotechnology Co.,Ltd.
Published by HT Digital Content Services with permission from Health Daily Digest....